11 Scopus citations

Abstract

The occurrence of stent thrombosis is one of the major obstacles limiting the long-term clinical efficacy of percutaneous coronary intervention. The anti-smooth muscle proliferation drugs coated on drug-eluting stents (DES) often indistinguishably block re-endothelialization, an essential step toward successful vascular repair, due to their nonspecific effect on endothelial cells (ECs). Therefore, identification of therapeutic targets that differentially regulate vascular smooth muscle cell (VSMC) and EC proliferation may lead to the development of ideal drugs for the next-generation DES. Our recent studies have shown that CTP synthase 1 (CTPS1) differentially regulates the proliferation of VSMC and EC after vascular injury. Therefore, CTPS1 inhibitors are promising agents for DES. In addition to CTPS1, other factors have also shown cell-specific effects on VSMC and/or EC proliferation and thus may become potential molecular targets for developing drugs to coat stents.

Original languageEnglish
Pages (from-to)21-23
Number of pages3
JournalExpert Review of Cardiovascular Therapy
Volume12
Issue number1
DOIs
StatePublished - Jan 2014

Keywords

  • cell proliferation
  • CTP synthase
  • drug-eluting stent
  • re-endothelialization
  • smooth muscle cell

Fingerprint

Dive into the research topics of 'Smooth muscle-specific drug targets for next-generation drug-eluting stent'. Together they form a unique fingerprint.

Cite this